ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of neffy for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, which allows neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.
äŒæ¥ã³ãŒãSPRY
äŒç€ŸåARS Pharmaceuticals Inc
äžå Žæ¥Dec 04, 2020
æé«çµå¶è²¬ä»»è
ãCEOãLowenthal (Richard E)
åŸæ¥å¡æ°155
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Dec 04
æ¬ç€Ÿæåšå°11682 El Camino Real, Suite 300
éœåžSAN DIEGO
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·92130
é»è©±çªå·18587719307
ãŠã§ããµã€ãhttps://ars-pharma.com/
äŒæ¥ã³ãŒãSPRY
äžå Žæ¥Dec 04, 2020
æé«çµå¶è²¬ä»»è
ãCEOãLowenthal (Richard E)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã